Acellular vaccines for ovine brucellosis: A safer alternative against a worldwide disease

Expert Review of Vaccines

Volumn 11, Issue 1, 2012, Pages 87-95

  Martins, Raquel Da Costa ^a   Irache, Juan M ^a   Gamazo, Carlos ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

acellular vaccine; adjuvant; brucellosis; microparticle; muscosal vaccination; nanoparticle

Indexed keywords

ACELLULAR VACCINE; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; ANTIIDIOTYPIC ANTIBODY; BACTERIAL ANTIGEN; BACTERIAL ENZYME; BACTERIAL PROTEIN; BACTERIN; BACTERIUM LIPOPOLYSACCHARIDE; BRUCELLA VACCINE; CALCIUM PHOSPHATE; CHOLERA TOXIN; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; DRUG CARRIER; ESCHERICHIA COLI ENTEROTOXIN; IMMUNOLOGICAL ADJUVANT; LIPOPOLYSACCHARIDE O; LUMAZINE SYNTHASE; MEMBRANE PHOSPHOLIPID; MIFAMURTIDE; OUTER MEMBRANE PROTEIN; PHOSPHORYL LIPID A; POLYMER; PROTEIN OMP19; RECOMBINANT PROTEIN; SUBUNIT VACCINE; SYNTHETASE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BRUCELLA; BRUCELLA ABORTUS; BRUCELLA CANIS; BRUCELLA CETI; BRUCELLA INOPINATA; BRUCELLA MELITENSIS; BRUCELLA MICROTI; BRUCELLA NEOTOMAE; BRUCELLA PINNIPEDIALIS; BRUCELLA SUIS; BRUCELLOSIS; COST BENEFIT ANALYSIS; DRUG COST; DRUG SAFETY; GAMMA IRRADIATION; HUMAN; IMMUNOGENICITY; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; REVIEW; SLAUGHTERHOUSE; VACCINATION; VACCINE PRODUCTION; ZOONOSIS;

ANIMALS; BRUCELLA MELITENSIS; BRUCELLA OVIS; BRUCELLA VACCINE; BRUCELLOSIS; HUMANS; SHEEP; SHEEP DISEASES; VACCINATION; VACCINES, ACELLULAR;

EID: 83155164585     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.172     Document Type: Review

References (86)

1. Seleem MN, Boyle SM, Sriranganathan N. Brucellosis: a re-emerging zoonosis. Vet. Microbiol. 140, 392-398 (2010).
2. Godfroid J, Cloeckaert A, Liautard JP et al. From the discovery of the Malta fever's agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re-emerging zoonosis. Vet. Res. 36, 313-326 (2005). (Pubitemid 40716368)
3. Ridler AL, West DM. Control of Brucella ovis Infection in Sheep. Vet. Clin. N. Am. Food Animal Pract. 27, 61-66 (2011).
4. Zinsstag J, Schelling E, Roth F, Bonfoh B, de Savigny D, Tanner M. Human benefits of animal interventions for zoonosis control. Emerg. Infect. Dis. 13, 527-531 (2007). (Pubitemid 46525097)
5. WHO/MZCP. Human and Animal Brucellosis. MZCP Report on the Third Workshop on Human and Animal Brucellosis Epidemiological Surveillance in the MZCP Countries. WHO, Geneva, Switzerland (1998).
6. WHO EMC/ZDI/98.14. WHO, Geneva, Switzerland (1997).
7. Blasco JM, Diaz R. Brucella melitensis Rev-1 vaccine as a cause of human brucellosis. Lancet 342, 805 (1993). (Pubitemid 23279816)
8. Kamboj M, Sepkowitz KA. Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient. Infect. Control Hosp. Epidemiol. 28, 702-707 (2007). (Pubitemid 46954757)
9. Blasco JM. A review of the use of B. melitensis Rev 1 vaccine in adult sheep and goats. Prev. Vet. Med. 31, 275-283 (1997). (Pubitemid 127378504)
10. Ariza J, Bosilkovski M, Cascio A et al. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med. 4, 317 (2007).
11. Schurig GG, Sriranganathan N, Corbel MJ. Brucellosis vaccines: past, present and future. Vet. Microbiol. 90, 479-496 (2002). (Pubitemid 35282500)
12. Marin CM, Barberan M, Jimenez De Bagues MP, Blasco JM. Comparison of subcutaneous and conjunctival routes of Rev1 vaccination for the prophylaxis of Brucella ovis infection in rams, Res. Vet. Sci. 48, 209-215 (1990). (Pubitemid 20136932)
13. Muñoz MP, De Miguel MJ, Grilló MJ, Marín CM, Barberán M, Blasco JM. Immunopathological responses and kinetics of Brucella melitensis Rev 1 infection after subcutaneous or conjunctival vaccination in rams. Vaccine 26, 2562-2569 (2008).
14. Moriyón I, Grilló MJ, Monreal D et al. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet. Res. 35, 1-38 (2004). (Pubitemid 38380146)
15. Schurig GG, Roop RM, Bagchi T, Boyle S, Buhrman D, Sriranganathan N. Biological properties of RB51; a stable rough strain of Brucella abortus. Vet. Microbiol. 28(2), 171-188 (1991).
16. el Idrissi AH, Benkirane A, el Maadoudi M, Bouslikhane M, Berrada J, Zerouali A. Comparison of the efficacy of Brucella abortus strain RB51 and Brucella melitensis Rev. 1 live vaccines against experimental infection with Brucella melitensis in pregnant ewes. Rev. Sci. Tech. 20, 741-747 (2001). (Pubitemid 33588918)
17. Jimenez de Bagues MP, Barberan M, Marin CM, Blasco JM. The Brucella abortus RB51 vaccine does not confer protection against Brucella ovis in rams. Vaccine 13, 301-304 (1995).
18. Villarroel M, Grell M, Saenz R. Isolation and identification of Brucella abortus RB 51 in human: first report in Chile. Arch. Med. Vet. 32, 89-91 (2000).
19. Cloeckaert A, Zygmunt MS, Nicolle J, Dubray G, Limet JN. O-chain expression in the rough Brucella melitensis strain B115: induction of O-polysaccharide-specific monoclonal antibodies and intracellular localization demonstrated by immunoelectron microscopy. J. Gen. Microb. 138, 1211-1219 (1992).
20. Adone R, Francia M, Ciuchini F. Evaluation of Brucella melitensis B115 as rough-phenotype vaccine against B. melitensis and B. ovis infections. Vaccine 26, 4913-4917 (2008).
21. Adone R, Francia M, Pistoia C, Pesciaroli M, Pasquali P. Brucella melitensis rough strain B115 is protective against heterologous Brucella spp. infections. Vaccine 29, 2523-2529 (2011).
22. Jacques I, Verger JM, Laroucau K et al. Immunological responses and protective efficacy against Brucella melitensis induced by bp26 and OMP31 B. melitensis Rev.1 deletion mutants in sheep. Vaccine 25, 794-805 (2007). (Pubitemid 44856131)
23. Grillo MJ, Marin CM, Barberan M et al. Efficacy of bp26 and bp26/OMP31 B. melitensis Rev.1 deletion mutants against Brucella ovis in rams. Vaccine 27, 187-191 (2009).
24. Arenas-Gamboa AM, Rice-Ficht AC, Kahl-McDonagh MM, Ficht TA. Protective efficacy and safety of Brucella melitensis 16MAmucR against Intraperitoneal and aerosol challenge in BALB/c mice. Infect. Immun. 79, 3653-3658 (2011).
25. Magnani DM, Harms JS, Durward MA, Splitter GA. Nondividing but Metabolically active g-irradiated Brucella melitensis is protective against virulent B. melitensis challenge in mice.. Infect. Immun. 77, 5181-5518 (2009).
26. He Y, Xiang Z. Bioinformatics analysis of Brucella vaccines and vaccine targets using VIOLIN. Immunome Res. 6(1), S5 (2010).
27. Cassataro J, Pasquevich KA, Estein SM et al. A recombinant subunit vaccine based on the insertion of 27 amino acids from OMP31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. Vaccine 25, 4437-4446 (2007). (Pubitemid 46695804)
28. Vizcaíno N, Kittelberger R, Cloeckaert A, Marín CM, Fernández-Lago L. Minor nucleotide substitutions in the omp31 gene of Brucella ovis result in antigenic differences in the major outer membrane protein that it encodes compared to those of the other Brucella species. Infect. Immun. 69, 7020-7028 (2001). (Pubitemid 32995462)
29. Da Costa Martins R, Irache JM, Blasco JM et al. Evaluation of particulate acellular vaccines against Brucella ovis infection in rams. Vaccine 28, 3038-3046 (2010).
30. Salas-Tellez E, Nunez del Arco A, Tenorio V, Diaz-Aparicio E, de la Garza M, Suarez-Guemes F. Subcellular fractions of Brucella ovis distinctively induce the production of interleukin-2, interleukin-4, and interferon-γ in mice. Can. J. Vet. Res. 69, 53-57 (2005). (Pubitemid 40192592)
31. Blasco JM, Gamazo C, Winter AJ et al. Evaluation of whole cell and subcellular vaccines against Brucella ovis in rams. Vet. Immunol. Immunopathol. 37, 257-270 (1993).
32. Munoz PM, Estevan M, Marin CM et al. Brucella outer membrane complex-loaded microparticles as a vaccine against Brucella ovis in rams. Vaccine 24, 1897-1905 (2006). (Pubitemid 43238272)
33. Tabatabai LB, Pugh Jr. GW. Modulation of immune responses in BALB/c mice vaccinated with Brucella abortus Cu-Zn superoxide dismutase synthetic peptide vaccine. Vaccine 12, 919-924 (1994).
34. Cassataro J, Velikovsky CA, De La Barrera S et al. A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response. Infect. Immun. 73, 6537-6546 (2005).
35. Onate AA, Cespedes S, Cabrera A et al. A DNA vaccine encoding Cu,Zn superoxide dismutase of Brucella abortus induces protective immunity in BALB/c mice. Infect. Immun. 71, 4857-4861 (2003). (Pubitemid 37070726)
36. Beauclair KD, Khansari DN. Protection of mice against Brucella abortus by immunization with polyclonal anti-idiotype antibodies. Immunobiology 180, 208-220 (1990). (Pubitemid 20080582)
37. Gamazo C, Winter AJ, Moriyon I, Riezu-Boj JI, Blasco JM, Diaz R. Comparative analyses of proteins extracted by hot saline or released spontaneously intoouter membrane blebs from field strains of Brucella ovis and Brucella melitensis. Infect. Immun. 57, 1419-1426 (1989). (Pubitemid 19114158)
38. Estein SM, Cassataro J, Vizcaino N, Zygmunt MS, Cloeckaert A, Bowden RA. The recombinant OMP31 from Brucella melitensis alone or associated with rough lipopolysaccharide induces protection against Brucella ovis infection in BALB/c mice. Microbes. Infect. 5, 85-93 (2003). (Pubitemid 36316050)
39. Edmonds MD, Cloeckaert A, Elzer PH. Brucella species lacking the major outer membrane protein OMP25 are attenuated in mice and protect against Brucella melitensis and Brucella ovis. Vet. Microbiol. 88, 205-221 (2002). (Pubitemid 34876574)
40. Berguer PM, Mundiñano J, Piazzon I et al. A polymeric bacterial protein activates dendritic cells via TLR4. J. Immunol. 176, 2366-2372(2006). (Pubitemid 43201685)
41. Costa Oliveira S, Souza de Oliveira F, Costa Macedo G et al. The role of innate immune receptors in the control of Brucella abortus infection: Toll-like receptors and beyond. Microbes. Infect. 10, 1005-1009 (2008).
42. Velikovsky CA, Goldbaum FA, Cassataro J et al. Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used. Infect. Immun. 71(10), 5750-5755 (2003). (Pubitemid 37205628)
43. Velikovsky CA, Cassataro J, Giambartolomei GH et al. A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB/c mice. Infect. Immun. 70(5), 2507-2511 (2002). (Pubitemid 34408394)
44. Cassataro J, Pasquevich KA, Estein SM et al. DNA vaccine coding for the chimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. Vaccine 25(22), 4437-4446 (2007). (Pubitemid 46695804)
45. Estein SM, Fiorentino MA, Paolicchi FA, Clausse M, Manazza J. The polymeric antigen BLSOmp31 confers protection against Brucella ovis infection in rams. Vaccine 27, 6704-6711(2009).
46. Mallapragada SK, Narasimhan B. Immunomodulatory biomaterials. Int. J. Pharm. 364, 265-271 (2008).
47. Gorvel JP. Brucella: a Mr Hide converted into Dr Jekyll. Microbes. Infect. 10, 1010-1013 (2008).
48. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat. Immunol. 12, 509-517 (2011).
49. Ardavin C. Origin, precursors and differentiation of mouse dendritic cells. Nat. Rev. Immunol. 3, 582-590 (2003). (Pubitemid 37328677)
50. Degen WG, Jansen T, Schijns VE. Vaccine adjuvant technology: From mechanistic concepts to practical applications. Expert Rev. Vaccines 2(2), 327-335 (2003). (Pubitemid 36559933)
51. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453, 1122-1126 (2008). (Pubitemid 351871731)
52. Lawson LB, Norton EB, Clements JD. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Curr. Opin. Immunol. 23(3), 414-420 (2011).
53. Lavelle EC. Generation of improved mucosal vaccines by induction of innate immunity. Cell Mol. Life Sci. 62, 2750-2770 (2005). (Pubitemid 41779945)
54. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 82, 488-496 (2004). (Pubitemid 39421058)
55. Pasquevich KA, Estein SM, Garcia Samartino C et al. Immunization with recombinant Brucella species outer membrane protein OMP16 or OMP19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection. Infect. Immun. 77, 436-445 (2009).
56. Pasquevich KA, Ibañez AE, Coria LM et al. An oral vaccine based on U-OMP19 induces protection against B. abortus mucosal challenge by inducing an adaptive IL-17 immune response in mice. PLoS ONE 6(1), e16203 (2011).
57. Tamayo I, Irache JM, Mansilla C, Ochoa-Reparaz J, Lasarte JJ, Gamazo C. Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation. Clin. Vacc. Immunol. 17, 1356-1362 (2010).
58. van der Lubben IM, Kersten G, Fretz MM, Beuvery C, Coos Verhoef J, Junginger HE. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 21, 1400-1408 (2003). (Pubitemid 36263181)
59. Adair BM. Nanoparticle vaccines against respiratory viruses. Wiley. Interdiscip. Rev. Nanomed. Nanobiotechnol. 1, 405-414 (2009).
60. Chiarella P, Massi E, De Robertis M, Signori E, Fazio VM. Adjuvants in vaccines and for immunisation: current trends. Expert. Opin. Biol. Ther. 7, 1551-1562 (2007). (Pubitemid 47597143)
61. Fahmy TM, Demento SL, Caplan MJ, Mellman I, Saltzman WM. Design opportunities for actively targeted nanoparticle vaccines. Nanomedicine 3, 343-355 (2008). (Pubitemid 351827311)
62. Chadwick S, Kriegel C, Amiji M. Nanotechnology solutions for mucosalimmunization. Adv. Drug Deliv. Rev. 62, 394-407 (2010).
63. Audran R, Peter K, Dannull J et al. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine 21, 1250-1255 (2003). (Pubitemid 36139957)
64. Thiele L, Rothen-Rutishauser B, Jilek S, Wunderli-Allenspach H, Merkle HP, Walter E. Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? J. Control. Release 76, 59-71 (2001). (Pubitemid 32786885)
65. Murillo M, Grillo MJ, Rene J et al. A Brucella ovis antigenic complex bearing poly-epsilon-caprolactone microparticles confer protection against experimental brucellosis in mice. Vaccine 19, 4099-4106 (2001). (Pubitemid 32703628)
66. Arenas-Gamboa AM, Ficht TA, Davis DS et al. Oral vaccination with microencapsuled strain 19 vaccine confers enhanced protection against Brucella abortus strain 2308 challenge in red deer (Cervus elaphus elaphus). J. Wildlife Dis. 45, 1021-1029 (2009).
67. Cassataro J, Pasquevich KA, Estein SM et al. A DNA vaccine coding for the chimera BLSOMP31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. Vaccine 25, 5958-5967 (2007). (Pubitemid 47082464)
68. Rosas G, Fragoso G, Ainciart N et al. Brucella spp. lumazine synthase: A novel adjuvant and antigen delivery system to effectively induce oral immunity. Microbes. Infect. 8, 1277-1286 (2006). (Pubitemid 43831691)
69. Ficht TA, Kahl-McDonagh M, Arenas- Gamboa M, Rice-Ficht AC. Brucellosis: the case for live, attenuated vaccines. Vaccine 27, D40-D43 (2009).
70. Nepom GT. Mucosal matters. Foreword. Nat. Rev. Immunol. 8, 409 (2008). (Pubitemid 351733424)
71. Arbos P, Campanero MA, Arangoa MA, Irache JM. Nanoparticles with specific bioadhesive properties to circumvent the pre-systemic degradation of fluorinated pyrimidines. J. Control. Release 96, 55-65 (2004). (Pubitemid 38438489)
72. Irache JM, Huici M, Konecny M, Espuelas S, Campanero MA, Arbos P. Bioadhesive properties of Gantrez nanoparticles. Molecules 10, 126-145 (2005). (Pubitemid 40404891)
73. Gomez S, Gamazo C, San Roman B et al. A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne. J. Immunol. Methods 348, 1-8 (2009).
74. Gomez S, Gamazo C, San Roman B et al. Allergen immunotherapy with nanoparticles containing lipopolysaccharide from Brucella ovis . Eur. J. Pharm. Biopharm. 70, 711-717 (2008).
75. Chen H. Recent advances in mucosal vaccine development. J. Control. Release 67, 117-128 (2008).
76. Clark MA, Blair H, Liang L, Brey RN, Brayden D, Hirst BH. Targeting polymerised liposome vaccine carriers to intestinal M cells. Vaccine 20, 208-217 (2001). (Pubitemid 32905334)
77. Salman HH, Gamazo C, de Smidt PC, Russell-Jones G, Irache JM. Evaluation of bioadhesive capacity and immunoadjuvant properties of vitamin B(12)-Gantrez nanoparticles. Pharm. Res. 25, 2859-2868 (2008).
78. Salman HH, Irache JM, Gamazo C. Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination. Vaccine 27, 4784-4790 (2009).
79. Salman HH, Gamazo C, Campanero MA, Irache JM. Bioadhesive mannosylated nanoparticles for oral drug delivery. J. Nanosci. Nanotechnol. 6, 3203-3209 (2006). (Pubitemid 44580001)
80. Keler T, Ramakrishna V, Fanger MW. Mannose receptor-targeted vaccines. Expert. Opin. Biol. Ther. 4, 1953-1962 (2004). (Pubitemid 39627146)
81. Apostolopoulos V, McKenzie IF. Role of the mannose receptor in the immune response. Curr. Mol. Med. 1(4), 469-474 (2001). (Pubitemid 33772953)
82. Jain SK, Gupta Y, Jain A, Saxena AR, Khare P. Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomedicine 4, 41-48 (2008). (Pubitemid 351324205)
83. Salman HH, Gamazo C, Agueros M, Irache JM. Bioadhesive capacity and immunoadjuvant properties of thiamine-coated nanoparticles. Vaccine 25, 8123-8132 (2007). (Pubitemid 350046324)
84. Schlosser E, Mueller M, Fischer S et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 26, 1626-1637 (2008).
85. Camacho AI, Da Costa Martins R, Tamayo I et al. Poly(methyl vinyl ether-co-maleic anhydride) nanoparticles as innate immune system activators. Vaccine 29(41), 7130-7135 (2011).
86. Lumsden JM, Pichyangkul S, Srichairatanakul U et al. Evaluation of the safety and immunogenicity in Rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-Like receptor 4 agonist formulated in an emulsion. Infect. Immun. 79, 3492-3500 (2011).